Apic Bio, Inc., a Cambridge, Mass.-based innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, completed a $40m Series A financing.
The round was led by Morningside Venture Investments, Ltd., with participation from existing investors The Alpha-1 Project (TAP) and A1ATD Investors and new investor ALS Investment Fund. In connection with the financing, Jason Dinges, Ph.D, J.D. from Morningside joins the board and Mr. Felix von Coerper from the ALS Investment Fund will become a board observer.
Led by John Reilly, CEO and Co-Founder, Scott Loiler, Ph.D., CTO, and Chris Mueller, Ph.D., Co-Founder and Associate Professor in the Department of Pediatrics, UMass Medical School, Apic Bio is developing treatment options for rare, devastating neurological and liver diseases. Its current pipeline focuses on new and effective treatments for Alpha-1 Antitrypsin Deficiency (Alpha-1, or AATD) and genetic Amyotrophic Lateral Sclerosis (ALS.)
The company intends to use the new capital to:
– advance its APB-101, APB-102 as well as preclinical Alpha-1 and ALS programs including gene insertion of AAT and targeting of the C9orf72 mutation, and
– support further discovery efforts leveraging its proprietary silence and replace THRIVE™ platform.